+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Advances in monoclonal antibody therapeutics

  • ID: 3428260
  • Report
  • Region: Global
  • 94 Pages
  • Frost & Sullivan
1 of 2
Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.
Note: Product cover images may vary from those shown
2 of 2
1. Executive Summary
  • Research Scope
  • Research Methodology
  • Key Findings
2. Monoclonal AntibodiesA Sneak Preview
  • Technology Snapshot – Multiple Segmentation
  • Industry Overview – Main Innovations
  • Industry Overview – Main Innovators
  • Technology Roadmap Toward Precision Medicine
3. Strategic Assessment of the Industry Environment
  • Therapeutic Areas and Clinical Indications
  • Molecular Agents and Cell Targets
  • Developmental Stage Focus
  • Market Potential
  • Market Evolution
  • Venture Capital Investment
  • Company Stage Investment Focus
  • Government Funding and Support
  • Worldwide Landscape
  • Key Drivers and Restraints
  • Key Technical and Business Challenges
4. Industry Best Practices and Strategic Insights
  • Industry Assessment – Partnerships and Alliances
  • Stakeholder Assessment for Partnerships
  • Partnerships and Alliances Models
  • Partnerships and Collaborations
  • Patent Analysis
  • Patent publishing trends
  • Patent office - wise distribution
5. Strategic Evaluation of R&D Portfolio
  • R&D Success and Key Performance Indicators
6. Key Contacts
  • Contacts
7. Appendix
  • Strategic R&D Pipeline – The Road Ahead
  • R&D Pipeline Assessment
  • Product Line Assessment
  • Abbreviations
  • Legal Disclaimer
Note: Product cover images may vary from those shown
3 of 2